Wisconsin Clinical Trials Report — July 2026

Wisconsin residents considering a clinical trial should act now if they match a study scheduled to close within the next 90 days. The state has 76 recruiting trials approaching closure, including 17 that accept healthy volunteers. Cancer studies make up many of the time-sensitive opportunities, particularly for prostate, breast, ovarian, endometrial, metastatic, and advanced solid tumors. Enrollment dates can change, and screening may take time, so prospective participants should contact study teams as soon as possible.

At the same time, Wisconsin added 21 new trials in July 2026, matching the 21 that opened in May. Across the state, 1,211 trials are currently recruiting through 651 research sites in 86 cities.

Closing trials create a narrow window for cancer patients and healthy volunteers

People with cancer have the largest concentration of studies nearing enrollment closure. Prostate cancer leads with 4 closing-soon trials, followed by breast cancer with 3. Several other cancer categories each account for 2 trials: metastatic solid tumors, metastatic cancer, ovarian cancer, advanced solid tumors, and endometrial cancer. Depression and asthma also appear in 2 closing-soon trials each, while hematologic tests account for 2.

• Prostate cancer — 4 closing-soon trials
• Breast cancer — 3
• Metastatic solid tumor, hematologic tests, metastatic cancer, ovarian cancer, advanced solid tumor, depression, endometrial cancer, and asthma — 2 each

Healthy adults also have a limited opportunity to participate. Seventeen of the 76 studies nearing closure accept healthy volunteers, while 139 healthy-volunteer trials are recruiting statewide overall. Anyone interested in a healthy-participant study should verify age, sex, medical-history, medication, and travel requirements directly with the research site, because a trial’s projected closing date does not guarantee that screening appointments will remain available.

July’s new studies span blood cancers, cardiometabolic health, and exercise

The new-trial mix is broad. Two studies opened for relapsed or refractory multiple myeloma, while other new research addresses B-cell non-Hodgkin lymphoma, chronic lymphocytic leukemia, cystic fibrosis, cognitive function, diet quality, cardiometabolic health, and exercise. One study focuses on athletes, and separate studies examine exercise response and exercise training.

• Relapsed or refractory multiple myeloma — 2 new trials
• B-cell non-Hodgkin lymphoma, cardiometabolic health, chronic lymphocytic leukemia, cognitive function, cystic fibrosis, diet quality, exercise response, exercise training, and athlete research — 1 each

Drug studies dominated the month, with 14 of the 21 new trials using a drug intervention. Other study types accounted for 5, behavioral research for 3, and biological and device studies for 2 each. The totals overlap because some trials can be categorized in more than one way.

Large Phase 3 studies from Amgen, AstraZeneca, and other sponsors

Several July launches stand out because of their late development phase, planned enrollment, or involvement of major pharmaceutical sponsors. Amgen’s Phase 3 MARITIME-1-EXTENSION study, NCT07684235, plans to enroll 3,200 people with obesity or overweight. The study evaluates the long-term efficacy, safety, and tolerability of maridebart cafraglutide and extends an earlier trial.

AstraZeneca opened two substantial Phase 3 programs. NCT07720284 plans to enroll 915 adults with high-risk muscle-invasive urothelial cancer and compares Dato-DXd plus rilvegostomig with standard care after radical resection. The study may last about 78 months from the first participant visit through the final participant visit, with treatment lasting up to about 12 months, depending on the participant’s treatment course.

• NCT07684235 — Amgen’s Phase 3 extension study evaluating maridebart cafraglutide for obesity or overweight, with 3,200 planned participants.
• NCT07720284 — AstraZeneca’s Phase 3 study of Dato-DXd plus rilvegostomig versus standard care for adults with high-risk residual muscle-invasive urothelial cancer.
• NCT07700979 — Akeso’s Phase 3 study of cadonilimab plus chemotherapy versus chemotherapy with or without nivolumab for previously untreated, unresectable, or metastatic gastric or gastroesophageal-junction adenocarcinoma; planned enrollment is 900.
• NCT07735637 — AstraZeneca’s DURGA-6 Phase 3 study comparing AZD0120 with autologous stem-cell transplantation as consolidation treatment for newly diagnosed, transplant-eligible multiple myeloma; planned enrollment is 750.
• NCT07728188 — AbbVie’s Phase 3 study of injected etentamig plus oral pomalidomide versus standard therapies for adults with relapsed or refractory multiple myeloma; planned enrollment is 520.

Other notable studies include NCT07702578, a Phase 3 TScan Therapeutics study of genetically engineered donor T cells after allogeneic stem-cell transplantation, with 310 planned participants. Bristol Myers Squibb is sponsoring NCT07680764, a Phase 2 study testing imzokitug with pumitamig and platinum-doublet chemotherapy against pumitamig and chemotherapy as first-line treatment for locally advanced or metastatic non-small cell lung cancer. The study plans to enroll 160 participants.

Wisconsin institutions are also central to the month’s activity. University of Wisconsin, Madison sponsored 5 new trials, while the Medical College of Wisconsin and University of Wisconsin, River Falls sponsored 2 each. AstraZeneca sponsored 3 new trials and Amgen sponsored 2. Overall, 11 new trials were industry-sponsored and 10 were classified as other, showing a close balance between commercial and non-industry research.

Madison and Milwaukee account for most new openings

New trial activity is concentrated in Wisconsin’s two largest research and medical centers. Madison recorded 11 new trials, more than half of the month’s openings. Milwaukee followed with 8. River Falls added 2, and Wauwatosa added 1.

• Madison — 11 new trials
• Milwaukee — 8
• River Falls — 2
• Wauwatosa — 1

This pattern points to a strong Madison–Milwaukee concentration, supported by major universities, academic medical centers, and specialized research sites. However, the broader statewide network includes 86 recruiting cities and 651 sites, so participants should search beyond the largest metro areas when a condition-specific option is scarce. River Falls and Wauwatosa offer additional access, particularly for people who can travel within western or southeastern Wisconsin.

Healthy volunteers, older adults, and families should check eligibility

Six of July’s 21 new trials accept healthy volunteers, adding to the 139 healthy-participant studies recruiting statewide. These opportunities may involve cardiometabolic health, cognitive function, exercise, diet, or other research questions rather than treatment of a diagnosed illness.

Eligibility is especially relevant for older adults: 14 of the new trials include older adults. One new study includes children, one is female-only, and one is male-only. These designations do not establish that every person in the demographic group will qualify; age, health history, medications, test results, and other criteria still apply.

Patients with prostate, breast, ovarian, endometrial, or other advanced cancers should review closing-soon studies immediately. People with multiple myeloma, lymphoma, leukemia, cystic fibrosis, or lung cancer may find newly opened options, while healthy volunteers and older adults have several entry points across behavioral, exercise, cardiometabolic, and drug research.

With the monthly number of new openings holding steady at 21 and enrollment deadlines approaching for 76 studies, Wisconsin’s trial landscape is likely to remain active through late summer. Checking listings early and asking sites about screening timelines will give eligible residents the best chance to enter a study before recruitment changes.